Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India.  BD 

The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences Practice.

Ajit Mahadevan told The Economic Times of India that credit restrictions will see biotechs increasingly turn to India.

This will help drive growth from its current $200m a year, to the $600m that KPMG predicted it would reach by 2010.

Related Reading:

Looking For A Job? Pharma and India are Looking

MSD Pharma (Merck subsidiary) to hire 1,500 people in India
WellPoint to begin pilot Medical Tourism program with India
Mayo Clinic Says Goodbye to clinical services in the US
US FDA to open office in New Delhi, Mumbai
Indian Pharma offshoring to be US $2.5bn opportunity by 2012


Post a Comment

Google Analytics Alternative